Search results for "Liver"

showing 10 items of 4961 documents

Acid‐Cleavable Poly(ethylene glycol) Hydrogels Displaying Protein Release at pH 5

2020

Abstract PEG is the gold standard polymer for pharmaceutical applications, however it lacks degradability. Degradation under physiologically relevant pH as present in endolysosomes, cancerous and inflammatory tissues is crucial for many areas. The authors present anionic ring‐opening copolymerization of ethylene oxide with 3,4‐epoxy‐1‐butene (EPB) and subsequent modification to introduce acid‐degradable vinyl ether groups as well as methacrylate (MA) units, enabling radical cross‐linking. Copolymers with different molar ratios of EPB, molecular weights (M n) up to 10 000 g mol−1 and narrow dispersities (Đ<1.05) were prepared. Both the P(EG‐co‐isoEPB)MA copolymer and the hydrogels showed pH‐…

540 Chemistry and allied sciencesVinyl CompoundsBiocompatible MaterialsDegree of polymerization010402 general chemistry01 natural sciencesCatalysisPolyethylene GlycolsPolymerizationchemistry.chemical_compoundHydrolysisPolymer chemistryPEG ratioCopolymermedicinehydrogelsPolymer Technologieschemistry.chemical_classificationFull PaperEthylene oxide010405 organic chemistryHydrolysisOrganic ChemistryBiochemistry and Molecular BiologyProteinsprotein releaseHydrogelsGeneral ChemistryPolymerFull PapersHydrogen-Ion ConcentrationVinyl etherPolymerteknologiPEG0104 chemical sciencescopolymerizationchemistry540 Chemiedrug deliverySelf-healing hydrogelsMethacrylatesBiokemi och molekylärbiologimedicine.drugChemistry – A European Journal
researchProduct

Investigation of charge ratio variation in mRNA – DEAE-dextran polyplex delivery systems

2019

Biomaterials 192, 612 - 620 (2019). doi:10.1016/j.biomaterials.2018.10.020

570Static ElectricityBiophysicsBioengineering02 engineering and technologyGene deliveryBiomaterials03 medical and health scienceschemistry.chemical_compoundDrug Delivery SystemsX-Ray DiffractionDynamic light scatteringddc:570Scattering Small AngleHumansRNA MessengerParticle Size030304 developmental biology0303 health sciencesMessenger RNAHeparinSmall-angle X-ray scatteringDEAE-DextranBiological activityDendritic CellsTransfection021001 nanoscience & nanotechnologySmall-angle neutron scatteringDextranchemistryMechanics of MaterialsCeramics and CompositesBiophysics0210 nano-technology
researchProduct

9-cis-Retinoic acid enhances fatty acid-induced expression of the liver fatty acid-binding protein gene

1997

The role of retinoic acids (RA) on liver fatty acid- binding protein (L-FABP) expression was investigated in the well differentiated FAO rat hepatoma cell line. 9-cis-Retinoic acid (9-ci's-RA) specifically enhanced L-FABP mRNA levels in a time- and dose-dependent manner. The higher induction was found 6 h after addition of 10 -6 M 9-CK-RA in the medium. RA also enhanced further both L-FABP mRNA levels and cytosolic L-FABP protein content induced by oleic acid. The retinoid X receptor (RXR) and the peroxisome proliferator-activated receptor (PPAR), which are known to be activated, respectively, by 9-c/s-RA and long chain fatty acid (LCFA), co-operated to bind specifically the peroxisome prol…

9-cw-Retinoic acidReceptors Retinoic Acid[SDV]Life Sciences [q-bio]Receptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorMyelin P2 ProteinMicrobodiesBiochemistry0302 clinical medicineStructural BiologyTumor Cells CulturedAlitretinoinchemistry.chemical_classification0303 health sciencesChemistryFatty AcidsDrug SynergismPeroxisomeNeoplasm Proteins9-cis-Retinoic acidLiverBiochemistryFree fatty acid receptorlipids (amino acids peptides and proteins)Peroxisome proliferator-activated receptor alphaLong chain fatty acidFatty Acid-Binding Protein 7DimerizationPeroxisome proliferator-activated receptor gammaCarcinoma HepatocellularBiophysicsNerve Tissue ProteinsTretinoinRetinoid X receptorFatty Acid-Binding ProteinsLiver fatty acid-binding protein03 medical and health sciencesGeneticsAnimalsRNA MessengerMolecular Biology030304 developmental biologyFAO hepatoma cellFatty acidCell BiologyFatty acidRatsRetinoid X ReceptorsGene Expression RegulationNuclear receptorGene expressionCarrier Proteins[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryTranscription FactorsFEBS Letters
researchProduct

Estudio del estrés oxidativo hepático asociado a la enfermedad de Alzheimer. Efecto del tratamiento con bexaroteno y/o genisteína

2013

La enfermedad de Alzheimer (EA) no tiene una etiología perfectamente definida. Una de las teorías que se barajan como causa de la EA es la del péptido β-amiloide (βA). Esta molécula es neurotóxica y es capaz de producir estrés oxidativo. Se forma principalmente en el cerebro y se acumula formando placas extracelulares. Se ha sugerido que el βA es el eje principal de la EA, y por tanto que a partir de esta molécula se desencadenan todos los procesos asociados a la EA, lo que se ha llamado la cascada amiloidea. Otra de las hipótesis es la que la relaciona con el estrés oxidativo. Este factor sería el agente que realmente provoca toda la serie de cambios descritos en los tejidos nerviosos, a t…

:CIENCIAS DE LA VIDA::Neurociencias::Neurofisiología [UNESCO]genisteintreatmentLRP-1bexaroteneUNESCO::CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Fisiología animaloxidative stressalzheimer's disease:CIENCIAS DE LA VIDA::Biología animal (Zoología) ::Fisiología animal [UNESCO]liverUNESCO::CIENCIAS DE LA VIDA::Neurociencias::NeurofisiologíaRAGE
researchProduct

Pain Neuroscience Education and Physical Therapeutic Exercise for Patients with Chronic Spinal Pain in Spanish Physiotherapy Primary Care: A Pragmati…

2020

Producción Científica

:Health Care::Health Services Administration::Patient Care Management::Delivery of Health Care [Medical Subject Headings]lcsh:MedicineChronic painEnsayo clínico controlado aleatoriolaw.invention:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Nervous System Physiological Phenomena::Central Nervous System Sensitization [Medical Subject Headings]0302 clinical medicineRandomized controlled triallawphysical exerciseNeuroscience educationHealth care:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity [Medical Subject Headings]030212 general & internal medicine:Health Care::Population Characteristics::Health::Mental Health [Medical Subject Headings]education.field_of_study:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Pain::Chronic Pain [Medical Subject Headings]Chronic pain:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Nervous System Physiological Phenomena::Nervous System Physiological Processes::Sensation::Pain::Pain Threshold [Medical Subject Headings]General MedicinePrimary care:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Personal Satisfaction [Medical Subject Headings]Ejercicio físico:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Randomized controlled trialchronic painchronic spinal painmedicine.medical_specialty:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings]PopulationChronic spinal painPhysical exerciseArticleEducación neurocientífica03 medical and health sciencesprimary careQuality of life (healthcare)medicine:Humanities::Humanities::Philosophy::Life::Quality of Life [Medical Subject Headings]educationpain neuroscience educationPain neuroscience educationbusiness.industry:Diseases::Musculoskeletal Diseases::Muscular Diseases::Musculoskeletal Pain [Medical Subject Headings]Public healthlcsh:RPhysical exerciseDolor crónicoAtención primariamedicine.diseaseClinical trialrandomized controlled trialPhysical therapy:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Neurologic Examination::Pain Measurement [Medical Subject Headings]businessNeuroscience030217 neurology & neurosurgeryJournal of Clinical Medicine
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Two cases of monomicrobial intraabdominal abscesses due to KPC - 3 Klebsiella pneumoniaeST258 clone

2011

Abstract Background Knowledge of the etiology of pyogenic liver and pancreatic abscesses is an important factor in determining the success of combined surgical and antibiotic treatment. Literature shows geographical variations in the prevalence and distribution of causative organisms, and the spread of Klebsiella pneumoniae carbapenemase-producing bacteria is an emerging cause of abdominal infections. Case presentation We herein describe two cases of intra-abdominal abscesses due to monomicrobial infection by Klebsiella pneumoniae Sequence Type 258 producing K. pneumoniae carbapenemase 3 (KPC-Kp). In case 1, a 50-year-old HIV-negative Italian woman with chronic pancreatitis showed infection…

<it>Klebsiellae pneumoniae</it>medicine.medical_specialtyAbdominal AbscessSettore MED/17 - Malattie Infettivecarbapenemasesmedicine.drug_classKlebsiella pneumoniaeAntibioticsMinocyclineCase ReportDrug resistanceTigecyclineTigecyclinebeta-LactamasesBacterial ProteinsDrug Resistance Multiple BacterialPancreatitis ChronicInternal medicinemedicineHumanslcsh:RC799-869Klebsiellae pneumoniaeSettore MED/12 - GastroenterologiabiologyColistinbusiness.industryAbdominal InfectionLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsElectrophoresis Gel Pulsed-FieldKlebsiella InfectionsSurgeryPancreatic NeoplasmsSettore MED/18 - Chirurgia GeneraleKlebsiella pneumoniaeColistinPancreatitislcsh:Diseases of the digestive system. Gastroenterologymonomicrobial abscess Klebsiellae pneumoniae carbapenemasesFemalebusinessmonomicrobial abscessmedicine.drugLiver abscessBMC Gastroenterology
researchProduct

Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

2021

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times ac…

ALBI grade; Barcelona Clinic Liver Cancer; Cancer of the Liver Italian Program; ITALICA staging system; MESIAHmedicine.medical_specialtylcsh:RC254-282GastroenterologyALBI gradeBarcelona Clinic Liver CancerInternal medicineMedicineIn patientCancer of the Liver Italian ProgramITALICA staging systemRadiologic ResponseSettore MED/12 - GastroenterologiaOriginal PaperHepatologybusiness.industryProportional hazards modelConfoundingHazard ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMESIAHOncologyHepatocellular carcinomaAkaike information criterionbusinessLiver cancer
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

AMPK regulates macrophage polarization in adipose tissue inflammation and NASH

2013

Molecular and Translational Medicine, Dept. of Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstrase 1,55116 Mainz, GermanyCOMMENTARY ON:Hematopoietic AMPK beta1 reduces mouse adipose tissue mac-rophage inflammation and insulin resistance in obesity. Galic S,Fullerton MD, Schertzer JD, Sikkema S, Marcinko K, Walkley CR,Izon D, Honeyman J, Chen ZP, van Denderen BJ, Kemp BE, Stein-berg GR. J Clin Invest 2011;121(12):4903–15. Copyright 2011.Reprinted with permission of American Society for ClinicalInvestigation.http://www.ncbi.nlm.nih.gov/pubmed/22080866Abstract: Individuals who are obese are frequently insulin resistant,putting them at increased risk of d…

AMPKmedicine.medical_specialtyMacrophageMacrophage polarizationAdipose tissueAdipose tissueM1M2Insulin resistanceInternal medicineNAFLDmedicineBeta oxidationchemistry.chemical_classificationHepatologybiologyGlucose transporterNASHFatty acidAMPKInsulin resistanceType 2 diabetesmedicine.diseaseFatty acidFibrosisEndocrinologychemistryLiverbiology.proteinGLUT4Research ArticleJournal of Hepatology
researchProduct